AbbVie's newest Juvéderm indication expands the filler portfolio into a high-volume treatment zone.
Allergan Aesthetics has secured FDA approval for Skinvive by Juvéderm for the improvement of neck appearance, specifically addressing neck lines and wrinkles. The approval marks the first and only FDA-cleared injectable hyaluronic acid filler indicated for this anatomical region.
Neck and décolletage treatments represent a natural adjacency for practices already performing facial rejuvenation. Skinvive is a smooth, cohesive gel formulation designed for superficial placement, distinct from volumizing fillers like Juvéderm Ultra or Voluma. The indication opens a new revenue stream in a zone where patients increasingly seek treatment but where options have historically been limited to lasers, RF microneedling, or off-label filler use.
First and only FDA-cleared injectable filler for neck appearance improvement.
For practices already integrated into the Allē loyalty ecosystem, this approval reinforces AbbVie's strategy of expanding indications within its core injectable portfolio rather than acquiring new platforms. Practices should expect promotional support and potential rebate incentives tied to Skinvive adoption.
Source: original report ↗
Frequently asked questions
Is Skinvive by Juvéderm FDA approved for neck wrinkles?
Yes, Allergan Aesthetics received FDA approval for Skinvive by Juvéderm specifically for improving neck appearance and addressing neck lines and wrinkles. It is the first and only FDA-cleared injectable hyaluronic acid filler indicated for the neck region.
What's the difference between Skinvive and other Juvéderm fillers?
Skinvive is a smooth, cohesive gel formulation designed for superficial placement in delicate areas like the neck and décolletage. Unlike volumizing fillers such as Juvéderm Ultra or Voluma, Skinvive is not intended for deep tissue augmentation.
Can medspa owners use Skinvive off-label for other areas?
Skinvive is FDA-cleared only for neck and décolletage treatment. While off-label use is a clinical decision, the approval specifically designates this indication, and practices should follow FDA guidance and their own risk management protocols for any off-label applications.
How does Skinvive fit into a medspa's treatment menu?
Skinvive opens a new revenue stream for practices already performing facial rejuvenation, as neck and décolletage treatments are a natural adjacency. It addresses a high-volume treatment zone where patients have historically had limited options beyond lasers, RF microneedling, or off-label filler use.
Will there be rebates or incentives for practices using Skinvive?
Practices integrated into the Allē loyalty ecosystem should expect promotional support and potential rebate incentives tied to Skinvive adoption as part of AbbVie's strategy to expand indications within its injectable portfolio.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/mo
Join the owners who run ahead of the industry. Cancel anytime, one click.
